Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | Skyrizi |
| Active Ingredient: | Risankizumab 90mg/mL |
| Dosage Form: | Solution for injection |
| New Zealand Sponsor: | AbbVie Limited |
| Manufacturers: | Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany AbbVie Biotechnology Limited, Barceloneta, Puerto Rico |
| Product: | Skyrizi (Pre-filled pen) |
| Active Ingredient: | Risankizumab 150mg/mL |
| Dosage Form: | Solution for injection |
| New Zealand Sponsor: | AbbVie Limited |
| Manufacturer: | AbbVie Biotechnology Limited, Barceloneta, Puerto Rico |
| Product: | Skyrizi (Pre-filled syringe) |
| Active Ingredient: | Risankizumab 150mg/mL |
| Dosage Form: | Solution for injection |
| New Zealand Sponsor: | AbbVie Limited |
| Manufacturer: | AbbVie Biotechnology Limited, Barceloneta, Puerto Rico |
Dated this 9th day of October 2023.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).